FILTER

Refine your search with the following facets to narrow down your results.

4 Current news of Resverlogix

Resverlogix Publishes Data Confirming RVX-208's Impact on Reverse Cholesterol Transport

10-Jun-2010 - Resverlogix announced that it has collaborated with the Division of Cardiology at the Research Institute of the McGill University Health Centre (RI of the MUHC), to publish in the Journal of American College of Cardiology (JACC), a report entitled 'RVX-208 A Small Molecule that Increases ...

atherosclerosis cardiology cardiovascular diseases +6

RVX-208 Exploratory Study Illustrates Early Potential for Alzheimer's Disease

12-Nov-2008 - Resverlogix Corp. announced that treatment with its lead drug RVX-208, a first in class ApoA-I/Prebeta-HDL elevating drug, in a post-hoc analysis from the Phase 1a clinical trial found that treatment with RVX-208 resulted in a positive trend on an important marker of cognitive function and ...

Alzheimer's disease amino acids cholesterol +5

Resverlogix' Phase 1b/2a Program Commences for RVX-208

27-Aug-2008 - Resverlogix Corp. announced that the Phase 1b/2a program for the study of RVX-208 in subjects with normal lipids and those with low high-density lipoprotein (HDL) cholesterol has proceeded according to plan. "We are very excited about moving forward into this important 28-day study with RVX-208. ...

atherosclerosis cardiovascular diseases cholesterol +2

Jan Gray Joins Resverlogix Board of Directors

29-Jul-2008 - Resverlogix Corp. announced effective immediately Jan Gray, CA has joined the Company's Board of Directors. Jan Gray, CA is a practicing chartered accountant who specializes in advising high net worth individuals with complex financial, investment and taxation issues. She is also Executive ...

Ernst & Young GE General Electric +1